ND4 COST-UTILITY OF INTERFERON BETA-1B IN THE TREATMENT OF PATIENTS WITH A CLINICALLY ISOLATED SYNDROME SUGGESTIVE OF MULTIPLE SCLEROSIS- MODEL UTILIZING FIVE YEAR BENEFIT DATA
Abstract
Authors
JP Caloyeras B Harrow C Wang K Beckmann V Knappertz C Pohl JD Miller MW Russell R Sandbrink K Gondek